Development of bioactive hydrolysate from marine by-products

Prosjektet PepSea har hatt som mål og utvikle produkter med høy verdi fa uutnyttet eller lite utnyttet marint materiale. Med hjelp fra Nofima, Marbio/UiT og andre FoU-institusjoner har bedriften Stella Polaris AS som mål og utvikle kosttilskudd, med offentlig godkjent helsepåstand, fra marint restråstoff. Produktene vil basere seg på råvarer med høyt innhold av protein, og utviklingsprosessen styres mot bioaktive peptider (proteinfragmenter) / peptidkonsentrater som kan tas oralt og som har en positiv effekt enten på Diabetes type 2, appetittregulering og fedme. Prosjektet vil ferdigstilles i 2019 og inkludere data fra preklinisk studie. Resultatene fra studie i dyremodell (Zucker obese rats) er evaluert med tanke på videreføring i klinisk studie. Etter lengre dialog med ulike kompetansepersoner i Norge og utlandet har en på bakgrunn av noe uklare og ikke statistisk signifikante resultater i dyrestudiet funnet å ikke videreføre prosjektet inn i en klinisk studie.

A large volume of marine by-products from the Norwegian fishery and fish industry are not exploited or are used to low value products In this project we want to develop and document bioactive products for dietary supplements related to the treatment of conditions related to metabolic syndrome. On the basis of six different marine products from cod, shrimp, snow crab, salmon and algae we will make hydrolysates with different enzymes and with different molecular weights and degree of hydrolysis. The different hydrolysates will be screened for bioactivity related to 1) Diabetes mellitus type 2, 2) High cholesterol (LDL) levels , 3) Appetite regulation and 4) Anti-adipocyte effect. Results will be analyzed with the help of peptide mapping and multivariate analysis prior to new production of hydrolysates based on the analysis followed by a second round of bioactivity screening for the same conditions. One or more hydrolysates, with satisfactory in-vivo bioactivity, will be processed in industrial scale at the National facility for marine bioprocessing (NAMAB) prior to further testing in animal model(s). A preclinical efficacy test, in animal model, is the last step in this project. Interesting effects will as a next step be evaluated for testing in humans (clinical trials). The project has a big potential to create novel products of high value from raw materials which is not exploited or are sold at a very low value. Stella Polaris has through its subsidiary company Marealis AS developed a hydrolysate (peptide concentrate) from shrimp shell with very promising effect on the reduction of elevated blood pressure. The product is currently documented for its effect in a clinical trial. Experience from this development will be used in the PepSea project.